(NASDAQ GS: CELG)
Attention investors who purchased shares of Celgene Corporation before January 3, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Celgene Corporation concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Bristol-Myers Squibb Company for approximately $74 billion.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Celgene Corporation (“Celgene” or the “Company”) (NASDAQ GS: CELG) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY) in a transaction valued at approximately $74 billion. Under the terms of the agreement, shareholders of Celgene will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene common stock. Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones.
If you own common stock of Celgene and purchased any shares before January 3, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.